Stockreport

Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]

Spyre Therapeutics, Inc.  (SYRE) 
PDF SPY001, an anti- a ß 7 antibody engineered for infrequent, subcutaneous dosing, demonstrated an updated half-life of 22 days, a greater than three-fold increase relativ [Read more]